ABIOMED

Abiomed is a provider of mechanical circulatory support devices and offers a continuum of care to heart failure patients. The Company develops, manufacture and market products that is designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. The Company's products are used in the cardiac catheterization lab (cath lab) by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces fourth quarter record revenue of $270 million, up 12% year over year.

Abiomed Announces Fourth Quarter Record Revenue of $270 Million, up 12% Year Over Year

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (Nasdaq: ABMD) announces the first patient in the world has been successfully implanted with Impella Bridge-to-Recovery (BTR).

World's First Patient Implanted with Impella BTR Minimally Invasive Heart Pump

BOSTON--(BUSINESS WIRE)---- $ABMD #NACD--Corporate governance award: NACD New England honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, Jack F. O'Brien on May 4

NACD New England Honors Boston Scientific, A.D. Makepeace, Rapid7 CEO Corey Thomas, Bennie Wiley, and Jack F.

Continued adoption of Abiomed's (ABMD) Impella 5.5 with SmartAssist is likely to provide a minimally invasive surgical option for acute heart failure patients.

Abiomed (ABMD) Announces Successful Usage of Impella in Japan

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, April 28, 2022, the Company will release financial results for the fourth quarter of the fiscal year 2022.

Abiomed Fourth Quarter Fiscal 2022 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--The first patient in Japan has been treated with Abiomed's Impella 5.5 with SmartAssist and the number of patients treated globally surpasses 5,000.

First Patient in Japan Treated with Impella 5.5 with SmartAssist

Edwards Lifesciences

Intuitive Surgical

Medtronic

Stryker

Thermo Fisher Scientific

With concerns about Covid-19 fading into the rearview mirror, the normalization of healthcare could benefit these medical device stocks. The post 7 Medical Device Stocks to Buy as Covid-19 Fears Fade appeared first on InvestorPlace.

7 Medical Device Stocks to Buy as Covid-19 Fears Fade

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to host investor call on Impella ECP, the world's smallest heart pump at 9 french.

Abiomed to Host Investor Call on Impella ECP, the World's Smallest Heart Pump at 9 French

DexCom

Fulgent Genetics

They have a whole lot going right, and little in the way of obstacles.

Got $5,000? 3 Growth Stocks to Buy That Could Double Your Money

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Here's Why You Should Retain Abiomed (ABMD) Stock For Now

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the SVB Leerink 11th Annual Global Healthcare conference.

Abiomed to Present at the SVB Leerink 11th Annual Global Healthcare Conference

Abiomed Inc. (ABMD) CEO Mike Minogue on Q3 2022 Results - Earnings Call Transcript

Abiomed's (ABMD) strength in Impella product revenues drives its Q3 top line.

Abiomed (ABMD) Beats on Q3 Earnings, Narrows FY22 Guidance

Abiomed (ABMD) delivered earnings and revenue surprises of 15.31% and 3.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Abiomed (ABMD) Q3 Earnings and Revenues Top Estimates

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces record revenue of $261 million, up 13% year over year. Increases low end of guidance: $1,025 Million - $1,030 Million, up 21% - 22%.

Abiomed Announces Record Revenue of $261 Million, up 13% Year Over Year

Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Abiomed (ABMD) to Report a Decline in Earnings: What to Look Out for

Abiomed's (ABMD) preCARDIA system has proven to be effective in reducing cardiac filling pressures and increasing urine output in ADHF patients.

Abiomed (ABMD) Reports Positive Data Backing preCARDIA System

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces that on Thursday, February 3, 2022, the Company will release financial results for the third quarter of the fiscal year 2022.

Abiomed Third Quarter Fiscal 2022 Earnings and Conference Call Notification

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed announces the successful results of the first-in-human early feasibility study of the preCARDIA system.

Early Feasibility Study Demonstrates Successful Use of Abiomed's preCARDIA Technology

DANVERS, Mass.--(BUSINESS WIRE)--Regulators in three countries have granted approvals to Abiomed's Impella surgical products.

Regulators Approve Impella 5.5 With SmartAssist in Japan and Hong Kong; US FDA Grants Impella BTR Conditional IDE Approval for First-in-Human Early Feasibility Study

Here is how Abiomed (ABMD) and Armata Pharmaceuticals, Inc. (ARMP) have performed compared to their sector so far this year.

Has Abiomed (ABMD) Outpaced Other Medical Stocks This Year?

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at the 40th annual J.P. Morgan Healthcare Conference.

Abiomed to Present at the 40th Annual J.P. Morgan Healthcare Conference

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed to present at upcoming investor conferences.

Abiomed to Present at Upcoming Investor Conferences

ORLANDO, Fla.--(BUSINESS WIRE)--Two large studies demonstrate complete revascularization with Impella heart pumps improves ejection fraction and long-term patient outcomes.

Two Large Studies Demonstrate Complete Revascularization with Impella Heart Pumps Improves Ejection Fraction and Long-Term Patient Outcomes

DANVERS, Mass.--(BUSINESS WIRE)--The 2021 ESC guidelines for treatment of acute heart failure patients elevate technology such as Impella to Class IIa ("should be considered").

News for ABIOMED Stock (ABMD)